|
Figure 1 Expression of cnrip1 in early Xenopus development. (A) qRT-PCR analysis of cnrip1 mRNA expression during Xenopus
development. The expression level of cnrip1 was normalized to that of ornithine decarboxylase (odc). The bar graph indicates the average
ratio of the normalized expression level in each stage to that in stage 33/34, from three independent experiments. The error
bar represents SD. (BâQ) Whole-mount in situ hybridization for cnrip1 mRNA at stage 10.5 (B, C), 12 (D, E), 15 (F, G), 19 (H,
I), 25 (J-M), 33/34 (N-Q). (B, D) Animal views. (C, E) Lateral views with blastopores downwards (arrowheads). (F, H, M, Q)
Dorsal views with anterior upwards. (G, K) Anterior views with dorsal upwards. (I, J, N) Lateral views with dorsal upwards and
anterior leftwards. (L) A transverse trunk section of the middle part of a stage 25 embryo. (O) A magnified view of the stage 33/
34 embryo shown in N. (P) A transverse trunk section of the middle part of a stage 33/34 embryo. anp, anterior neural plate; np,
neural plate; nt, neural tube; not, notochord; cg, cement gland; tp, trigeminal placode; op, olfactory placode; fb, forebrain; pg,
pineal gland; mb, midbrain; hb, hindbrain; e, eye; ap, alar plate; bp, basal plate.
|
|
Figure 2 cnrip1 knockdown disrupts eye and neural development. (A) Control MO or cnrip1 MO (40 ng each/embryo) was coinjected
with N- or C-terminally myc-tagged cnrip1 mRNA (1 ng each/embryo) at the 2-cell stage. GFP mRNA (200 pg/
embryo) was also co-injected to check that the injection was successful and that the protein loading was controlled. Injected
embryos were collected at stage 10.5 and extracted for immunoblotting analysis. (B, C) Control MO, cnrip1 MO or cnrip1-5mis
MO (10 ng each/blastomere) was injected into the animal region of two dorsal blastomeres at the 4-cell stage. The representative
results from three independent experiments are shown. (B) Stage 19, anterior views with dorsal upwards. Embryos injected with
control MO developed normally (100%, n = 65). Embryos injected with cnrip1 MO displayed open neural tube defects (96%,
n = 72). Embryos injected with cnrip1-5mis MO developed normally (100%, n = 70). (C) Stage 37/38, lateral views with dorsal
upwards and anterior leftwards. Embryos injected with control MO developed normally (100%, n = 65). Embryos injected with
cnrip1 MO displayed head defects, eye defects and shortened curved body axes (100%, n = 72). Embryos injected with cnrip1-
5mis MO developed normally (100%, n = 70).
|
|
Figure 3 cnrip1 knockdown reduces expression of sox2, otx2, pax6 and rax. (A) qRT-PCR analysis for the pan-neural marker
sox2 (stage 10.5 and 12.5), the anterior marker otx2 (stage 10.5 and 12.5), the eye and neural marker pax6 (stage 12.5 and 24) and
the eye marker rax (stage 12.5 and 24) in embryos injected with control MO or cnrip1 MO (10 ng each/blastomere) into the animal
region of two dorsal blastomeres at the 4-cell stage. The expression level of each gene was normalized to that of odc. Values
are mean SD of three independent experiments; **P < 0.01; *P < 0.05. (B) Whole-mount in situ hybridization was carried out
on MO-injected embryos. Control MO or cnrip1 MO (10 ng each) was injected into the animal region of the left dorsal blastomere
at the 4-cell stage. The expression of sox2, otx2, pax6 and rax was reduced in 100% of cnrip1 MO-injected embryos (sox2,
stage 10.5, n = 20; sox2, stage 12.5, n = 24; otx2, stage 10.5, n = 20; otx2, stage 12.5, n = 24; pax6, stage 12.5, n = 30; pax6, stage
24, n = 24; rax, stage 12.5, n = 24; rax, stage 24, n = 24). Anterior views with dorsal upwards. The representative results from
two (sox2, stage 10.5; otx2, stage 10.5) or three (sox2, stage 12.5; otx2 stage 12.5; pax6, stage 12.5 and 24; rax, stage 12.5 and 24)
independent experiments are shown. The black brackets indicate MO-injected left sides. The dashed lines indicate midlines of
embryos.
|
|
Figure 4 Effects of cnrip1 over-expression on spatial expression patterns of sox2, otx2, pax6 and rax. Whole-mount in situ hybridization
analysis was carried out on embryos uninjected or injected with 500 pg of cnrip1 mRNA into the left dorsoanimal blastomere
at the 8-cell stage. The representative results from two (B, C) or three (A, D, E) independent experiments are shown.
Anterior views with dorsal upwards. The black brackets indicate mRNA-injected left sides. The dashed lines indicate midlines of
embryos. (A) sox2 expression at stage 12.5. Injected sides of embryos (n = 24) displayed expanded expression (29%, second and
third left) or no obvious change (71%, fourth left to rightmost). (B) otx2 expression at stage 12.5. Injected sides of embryos
(n = 20) displayed expanded expression (15%, second and third left) or no obvious change (85%, fourth left to rightmost). (C)
otx2 expression at stage 24. Injected sides of embryos (n = 22) displayed expanded expression (23%, second and third left),
expanded expression in the brain but reduced expression in the eye (14%, fourth left), or no obvious change (64%, rightmost and
second right). (D) pax6 expression at stage 24. Injected sides of embryos (n = 32) displayed expanded expression (31%, second and
third left), expanded expression in the brain but reduced expression in the eye (34%, fourth left), or no obvious change (34%,
rightmost and second right). (E) rax expression at stage 24. Injected sides of embryos (n = 30) displayed expanded expression
(47%, second and third left), reduced expression (10%, fourth left), or no obvious change (43%, rightmost and second right).
|
|
Figure 5 Partial rescue of eye defects in cnrip1 knockdown embryos. Cnrip1 MO (5 ng) was co-injected with or without myccnrip1
mRNA (350 pg) into the left dorsoanimal blastomere of 8-cell stage embryos. Injected embryos were cultured until stage
37/38. (A) The respective morphologies are shown as lateral views with anterior leftwards and dorsal upwards. (B) Left bar, 64%
of embryos injected with cnrip1 MO alone exhibited severe eye defects (absent or very small eyes). Seventy-one embryos were
examined in three independent experiments. Right bar, 51% of embryos injected with cnrip1 MO plus myc-cnrip1 mRNA displayed
severe eye defects. Ninety-six embryos were examined in three independent experiments. Values are mean SD of the
percentages of embryos with severe eye defects from three independent experiments; *P < 0.05. âVery small eyesâ include small
eyes with a dot-like, crescent, or gibbous shape, but not small eyes with a nearly round shape.
|
|
Figure 6 Knockdown of cnrip1 in the D1.1 blastomere, but
not in the D1.2 blastomere, causes eye and head defects. (A)
Schematic diagram of a 16-cell stage Xenopus laevis embryo.
(BâE) Cnrip1 MO (2.5 ng) was injected into the left D1.1 or
D1.2 blastomere at the 16-cell stage, and injected embryos
were cultured until stage 41. The uninjected right sides served
as controls. The representative results from two independent
experiments are shown. (B, D) Lateral views with anterior
leftwards and dorsal upwards. (C, E) Dorsal views with anterior
upwards. (B, C) Embryos injected with cnrip1 MO into
the left D1.1 blastomere showed eye and head defects in the
left sides (100%, n = 40). (D, E) Embryos injected with cnrip1
MO into the left D1.2 blastomere showed no significant
defects in eyes and heads, but exhibited slight bending of axes
to the left (90%, n = 40).
|
|
Figure 7 cnr1 knockdown leads to eye defects. (A) qRT-PCR analysis of cnr1 mRNA expression during Xenopus laevis development.
The expression level of cnr1 was normalized to that of odc. The bar graph indicates the ratio of the normalized expression level
in each stage to that in stage 33/34, from each of two independent experiments. (B) Whole-mount in situ hybridization for cnr1
mRNA. The representative results from two independent experiments are shown. Anterior is upwards in the dorsal view and leftwards
in the lateral views. Dorsal is upwards in lateral and anterior views. The lateral view of a stage 33/34 embryo is magnified in
the lower middle panel. e, eye; br, brain. (C, D) Control MO, cnr1 MO1, cnr1-5mis MO or cnr1 MO2 (20 ng each/blastomere)
was injected into the animal region of two dorsal blastomeres at the 4-cell stage. Injected embryos were cultured until stage 41. Lateral
views with anterior leftwards and dorsal upwards. Representative results from three independent experiments are shown. (C)
Embryos injected with either control MO or cnr1-5mis MO developed normally (control MO, 100%, n = 60; cnr1-5mis MO,
100%, n = 60), whereas those injected with cnr1 MO1 displayed eye defects (100%, n = 60). (D) Embryos injected with control
MO developed normally (100%, n = 60), whereas those injected with cnr1 MO2 displayed eye defects (100%, n = 60).
|
|
Figure 8 Effects of cnr1 knockdown on expression of sox2, otx2, pax6 and rax. (A) qRT-PCR analysis for marker gene expression
in embryos injected with control MO or cnr1 MO1 (20 ng each/blastomere) into the animal region of two dorsal blastomeres at
the 4-cell stage. The expression level of each gene at stage 12.5 or 24 was normalized to that of odc. Values are mean SD of
three independent experiments; *P < 0.05. (B, C) Whole-mount in situ hybridization analysis was carried out on embryos injected
with 20 ng of control MO or cnr1 MO1 into the animal region of the left dorsal blastomere at the 4-cell stage. The representative
results from two independent experiments are shown. Anterior views with dorsal upwards. The black brackets indicate MOinjected
left sides. The dashed lines indicate midlines of embryos. (B) A mild reduction of pax6 expression in the cnr1 MO1-
injected side was observed at stage 12.5 (52%, n = 21) and stage 24 (39%, n = 18). (C) A mild reduction of rax expression in the
cnr1 MO1-injected side was observed at stage 12.5 (44%, n = 18) and stage 24 (56%, n = 16).
|
|
cnrip1 (cannabinoid receptor interacting protein 1) gene expression in Xenopus laevis embryo, assayed via in situ hybridization, NF stage 12, dorsal view, anterior up.
|
|
cnrip1 (cannabinoid receptor interacting protein 1) gene expression in Xenopus laevis embryo, assayed via in situ hybridization, NF stage 19, lateral view, anterior left, dorsal up.
|
|
cnrip1 (cannabinoid receptor interacting protein 1) gene expression in Xenopus laevis embryo, assayed via in situ hybridization, NF stage 25, lateral view, anterior left, dorsal up.
|
|
cnrip1 (cannabinoid receptor interacting protein 1) gene expression in Xenopus laevis embryo, assayed via in situ hybridization, NF stage 33, lateral view, anterior left, dorsal up.
|
|
cnr1 (cannabinoid receptor 1 (brain)) gene expression in Xenopus laevis embryo, assayed via in situ hybridization, NF stage 33, lateral view, anterior left, dorsal up.
|